Opendata, web and dolomites


Unraveling the conceptional novel ADAM17 regulation by PP2A in metastasis formation.

Total Cost €


EC-Contrib. €






 UNNAMEd-2 project word cloud

Explore the words cloud of the UNNAMEd-2 project. It provides you a very rough idea of what is the project "UNNAMEd-2" about.

significantly    tumour    zebrafish    silac    group    regulates    first    dr    cancers    mouse    metastasis    protein    multiple    expression    clinical    cancer    showing    adam17    aberrant    spectrometry    patients    pave    therapeutics    drugs    signals    therapies    patient    hypothesis    interplay    epidermal    almost    pool    binds    screening    metalloproteinase    regulation    mechanisms    enzyme    pp2a    mutants    binding    deaths    negative    unpublished    treatments    functional    receptor    resistance    strategy    mass    inhibits    spread    understand    molecular    depletion    failed    representing    mutagenesis    models    negatively    showed    vitro    urgently    release    thereby    survival    choices    clinically    data    treat    mechanism    crispr    kveiborg    coupled    egfr    interaction    functionally    hypothesize    around    expand    anti    collaborators    urgent    colon    treatment    therapeutic    regulator    reduce    vivo    cells    discoveries    axis    phosphatase    adam    ligands    unravel    90    17    cas9    disintegrin    ligand   

Project "UNNAMEd-2" data sheet

The following table provides information about the project.


Organization address
address: NORREGADE 10
postcode: 1165

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00


 Project objective

Around 90% of all cancer-related deaths are due to metastasis. Understanding the process of cancer metastasis is therefore of urgent need to develop new treatments. Aberrant expression of the epidermal growth factor receptor (EGFR), or increased availability of its ligands promote tumour survival and metastasis in multiple cancers. As a result, several anti-EGFR therapeutics are in clinical use, but almost all patients will develop resistance against the treatment. Another strategy to treat EGFR driven cancers is to reduce the pool of available EGFR ligands. The crucial enzyme in EGFR ligand release is A Disintegrin And Metalloproteinase (ADAM) 17. I have unpublished data showing that depletion of ADAM17 significantly inhibits colon cancer growth and metastasis in vivo. However, anti-ADAM17 therapies have failed clinically and thus, we urgently need to understand the regulation of ADAM17. Recent discoveries by Dr. Kveiborg’s group, and collaborators showed that the protein phosphatase PP2A binds to ADAM17, and negatively regulates EGFR ligand release, thereby representing the first known negative regulator for ADAM17. Based on these novel findings, I hypothesize that the PP2A-ADAM17-EGFR axis has the ability to control cancer metastasis. To test this hypothesis, I aim to characterize the functional impact of the PP2A-ADAM17 interaction in cancer spread by creating ADAM17 mutants with different PP2A binding properties in colon cancer cells using CRISPR/Cas9 and functionally evaluate these cells in vitro and in zebrafish and mouse models. Moreover, I aim to unravel the molecular mechanisms of the interplay; applying SILAC coupled mass spectrometry and mutagenesis screening, to evaluate the mechanism by which PP2A affects ADAM17, and the signals involved in PP2A binding. This work will pave the way for the development of novel anti-cancer drugs and thereby expand the therapeutic choices for EGFR driven cancers and improve the patient survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UNNAMED-2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UNNAMED-2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EOBRECA (2019)

Differential Roles of Estrogens in Obesity-mediated ER+ Breast Cancer Development

Read More  

RETHEIR (2019)

The return of the heirs

Read More  

ShaRe (2019)

The potential of Sharing Resources for mitigating carbon emissions and other environmental impacts

Read More